156 related articles for article (PubMed ID: 21742423)
1. JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.
Tefferi A; Pardanani A
Blood Rev; 2011 Sep; 25(5):229-37. PubMed ID: 21742423
[TBL] [Abstract][Full Text] [Related]
2. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
LaFave LM; Levine RL
Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Stein BL; Crispino JD; Moliterno AR
Curr Opin Oncol; 2011 Nov; 23(6):609-16. PubMed ID: 21993415
[TBL] [Abstract][Full Text] [Related]
5. Investigational Janus kinase inhibitors.
Tam CS; Verstovsek S
Expert Opin Investig Drugs; 2013 Jun; 22(6):687-99. PubMed ID: 23432430
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
Pardanani A; Vannucchi AM; Passamonti F; Cervantes F; Barbui T; Tefferi A
Leukemia; 2011 Feb; 25(2):218-25. PubMed ID: 21079613
[TBL] [Abstract][Full Text] [Related]
8. Advances in the discovery of selective JAK inhibitors.
Menet CJ; Rompaey LV; Geney R
Prog Med Chem; 2013; 52():153-223. PubMed ID: 23384668
[TBL] [Abstract][Full Text] [Related]
9. [Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2015 Feb; 56(2):150-8. PubMed ID: 25765794
[TBL] [Abstract][Full Text] [Related]
10. New generation small-molecule inhibitors in myeloproliferative neoplasms.
Passamonti F; Maffioli M; Caramazza D
Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
[TBL] [Abstract][Full Text] [Related]
11. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
Pardanani A
Leukemia; 2008 Jan; 22(1):23-30. PubMed ID: 17882282
[TBL] [Abstract][Full Text] [Related]
12. Therapy with JAK2 inhibitors for myeloproliferative neoplasms.
Santos FP; Verstovsek S
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1083-99. PubMed ID: 23009939
[TBL] [Abstract][Full Text] [Related]
13. Emerging targeted therapies in myelofibrosis.
Barosi G
Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
[TBL] [Abstract][Full Text] [Related]
14. The future of JAK inhibition in myelofibrosis and beyond.
Mascarenhas JO; Cross NC; Mesa RA
Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
[TBL] [Abstract][Full Text] [Related]
15. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
Tefferi A
Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
[TBL] [Abstract][Full Text] [Related]
16. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
Assi R; Verstovsek S; Daver N
Curr Opin Hematol; 2017 Mar; 24(2):115-124. PubMed ID: 28072602
[TBL] [Abstract][Full Text] [Related]
17. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
18. Preclinical and clinical activity of ATP mimetic JAK2 inhibitors.
Wadleigh M; Tefferi A
Clin Adv Hematol Oncol; 2010 Aug; 8(8):557-63. PubMed ID: 20966892
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Quintás-Cardama A; Kantarjian H; Cortes J; Verstovsek S
Nat Rev Drug Discov; 2011 Feb; 10(2):127-40. PubMed ID: 21283107
[TBL] [Abstract][Full Text] [Related]
20. The many faces of Janus kinase.
Seavey MM; Dobrzanski P
Biochem Pharmacol; 2012 May; 83(9):1136-45. PubMed ID: 22209716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
